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The use of methylene blue as an 
surgical marker impairs vascular 
human saphenous veins 
extravascular 
responses of 
Methylene blue is occasionally applied to the adventitia of blood vessels during coronary artery bypass 
and other vascular procedures to assist in the orientation of the vessel. Inherent in this method is the 
assumption that extravascular pplication of methylene blue is innocuous with regard to vascular 
function. In the first part of this study, the in vitro vascular eactivity of methylene blue-labeled 
saphenous veins was compared with that of veins that were not marked with methylene blue. The 
vasoactive agents tested were designed to examine multiple pathways. They included potassium chloride, 
prostaglandin F2,~, phenylephrine, serotonin, angiotensin H, BHT-933 (~z-adrenergic agonist), sodium 
nitroprusside, acetylcholine, isoproterenol, and verapamil. Compared with unmarked veins, those 
marked with methylene blue demonstrated a significant impairment of both vasoconstrictor and 
vasodilator function. These observations were made on a relatively small number of patients and could 
therefore be attributed to inherent differences between patients or surgical procedures. In the second part 
of this study, these variables were eliminated by dividing a single vein from one patient into three 
segments for a 45-minute xposure to external only methylene blue, internal and external methylene 
blue, or no methylene blue. The segments were then evaluated for vasoreactivity in vitro. Externally 
applied methylene blue reduced vasoconstriction regardless of the agonist. Further, both endothelium- 
dependent and -independent vasodilation was diminished by external methylene blue exposure. In veins 
exposed to methylene blue both internally and externally the results were similar but the magnitude of 
impairment greater. It is concluded that surgical marking of blood vessels with methylene blue has the 
potential to adversely affect vascular eactivity and therefore the use of alternative dyes should be 
considered. (J THORAC CARDIOVASC SURG 1995;109:21-9) 
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dures to assist in the orientation of the blood vessel. 
The use of marking dyes serves to facilitate isolation 
and may therefore reduce surgical trauma. This is 
particularly true with microvascular operations in 
which vascular torsion can be reduced by the use of 
marking dyes.1 Procedural trauma to blood vessels is 
a legitimate practical concern, especially when con- 
sidering the functional importance of the delicate 
endothelium. The use of MB as a marking dye is 
thought o be innocuous on the basis of the assump- 
tion that application to the adventitia is unlikely to 
significantly penetrate the smooth muscle or endo- 
thelium. However, a recent report by Mazmanian 
and associates 2 suggests that MB applied to the 
adventitia has significant pharmacologic actions in 
rat tail arteries at doses 100 times lower than the 
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Fig. 1. Maximal vasoconstrictor responses measured in grams of tension in saphenous veins which were 
unmarked (open column, no MB, n = 12/72) or marked (black column, MB, n = 5/24) with MB during 
operations in which coronary artery bypass is used. A, Constriction elicited by membrane depolarization 
induced by KC1, 100 mmol/L. B, Constriction elicited by exposure to PGF2~, 3 txmol/L. No significant 
differences were detected. 
conventional 1% MB stock solution used for surgi- 
cal marking. Further, Bentz and coworkers 3 used an 
in vitro human arterial model to demonstrate that 
topical MB may increase platelet deposition. There- 
fore, careful reevaluation of MB as a surgical 
marker seems prudent. In this study, we evaluate the 
potential of MB to affect the in vitro vascular 
reactivity of human saphenous veins using two inde- 
pendent approaches. 
Materials and methods 
Vascular procurement. Sections of saphenous vein 
were randomly obtained from 23 patients undergoing 
coronary artery bypass grafting. The vessels were imme- 
diately transported to the laboratory in a modified Krebs- 
Henseleit buffer of the following composition: NaC1, 118.0 
mmol/L; KC1, 4.7 mmol/L; MgSO4, 1.2 mmol/L; KH2PO4, 
1.1 mmol/L; CaCl2, 2.5 mmol/L; NaHCO3, 25.0 mmol/L; 
dextrose, 10.0 mmol/L; indomethacin, 2.8 /,mol/L; and 
sodium ethylenediaminetetraacetic acid, 10 /,mol/L; 
25 ° C, pH 7.4, previously aerated with 95% oxygen and 
5% carbon dioxide, and sealed. The vein was carefully 
cleaned of all surrounding fat and connective tissue and 
cut into 4 mm rings. The vascular ings were suspended 
between two metal hooks in a 10 ml tissue bath containing 
identical buffer at 37°C continuously aerated with 95% 
oxygen and 5% carbon dioxide. The vascular isometric 
tension was measured with a Grass FT 03 force-displace- 
ment transducer (Grass Instrument Co., Quincy, Mass.) 
integrated to a low-level direct-current amplifier ecord- 
ing on a paper-charted polygraph (Beckman R611; Beck- 
man Instruments, Inc., Fullerton, Calif.). The rings were 
stretched to optimal diastolic resting tension as deter- 
mined in pilot studies (2 gm) and allowed 45 minutes to 
equilibrate before initiation of protocols. Bath solutions 
were changed every 20 minutes throughout all experi- 
ments. The time between tissue harvest and initiation of 
protocols was less than 3 hours. 
Protocols. For the first set of experiments, responses of 
saphenous veins that had been marked with MB (n = 
5/24) in the operating room were compared with un- 
marked veins (n = 12/72). After equilibration, all rings 
were constricted with KC1 at a concentration of 100 
mmol/L and then washed. Vasoconstrictor dose response 
curves were obtained by exposing each ring to increasing 
concentrations of only one of the following: phenyleph- 
fine, serotonin, angiotensin II, or the %-adrenergic ago- 
nist BHT-933 (BHT). After washout, the vessels were 
preconstricted with prostaglandin F2~ (PGFa~) 3 txmol/L. 
Vasodilator dose response curves were then obtained by 
exposing each vascular ing to increasing concentrations 
of only one of the following: sodium nitroprusside, ace- 
tylcholine, isoproterenol, or verapamil. According to this 
design, each ring was exposed to only one vasoconstrictor 
and one vasodilator (plus KC1 and PGF2,~). The order of 
drug administration was randomized. 
For the second set of experiments, an unmarked saphe- 
nous vein was cut into three segments, each 3 to 4 cm long 
(n = 6/36). One segment was tightly ligated with suture at 
both ends. The ligated segment and an unligated segment 
were placed in continuously aerated Krebs buffer contain- 
ing 0.1% MB (2.7 mmol/L). This dose of MB is 10 times 
lower than the conventional MB solution used to mark 
veins in the operating room. The remaining venous seg- 
ment was placed in an identical buffer without MB. After 
45 minutes, the segments were removed and extensively 
washed with Krebs solution. The exposure time was based 
on the estimated average time that a vein is exposed to 
MB from the time of marking to transplantation during a 
bypass procedure. Two vascular ings from each segment 
were cut and suspended in the tissue bath as described 
earlier. The ligated vessels that had been placed in the MB 
buffer served as the "external MB" group. The unligated 
vessels exposed to MB buffer and the unligated vessels 
exposed to MB-free buffer served as the "internal/external 
MB" group and the "MB-free" group (control), respec- 
tively. After equilibration, all rings were constricted with 
KC1 100 mmol/L and then washed. Vasoconstrictor dose 
response curves were obtained by exposing each ring to 
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Fig. 2. Vasoconstrictor dose response curves for phenylephrine (A), serotonin (B), angiotensin II (C), and 
BHT (D) obtained from saphenous vein ring preparations that were unmarked (open circles, no MB, n = 
12/18) or marked (black circles, MB, n = 5/6) with MB during operations for use in coronary artery bypass. 
Symbols on the X-axis depict ECso values for the respective curve. *p < 0.05. 
increasing concentrations of either phenylephrine or se- 
rotonin. After washout, the vessels were preconstricted 
with PGF2~ 3 /zmol/L and vasodilator dose response 
curves were obtained by exposing each ring to increasing 
concentrations of either sodium nitroprusside or acetyl- 
choline. As with the previous design, each ring was 
exposed to only one vasodilator. Gross and histologic 
examination at the conclusion of the experiment showed 
no visible MB on the endothelial surface of the ligated 
vessels. 
Data analysis. When enough tissue was available, the 
rings were run in pairs and the responses averaged to yield 
a single value. Therefore, all n values are presented as the 
number of patients followed by the number of ring 
preparations. In all cases, statistical analysis was per- 
formed with the number of patients used as the n value. 
MB impaired the ability of veins to constrict o both KC1 
and PGF2~. This impairment can potentially skew any 
data normalized to KC1 or PGF2~ responses. Therefore, 
vasoconstrictor responses are ported both in grams of 
tension and as a percentage of response to KC1. Likewise, 
vasodilator responses are presented as both a percentage 
of preconstriction and as grams of relaxation. Dose re- 
sponse curves were evaluated by an analysis of variance 
with a Scheffe's adjustment for multiple comparisons. For 
the first set of experiments in which the veins were from 
different patients, an unpaired t test was used to assess 
single KC1 and PGF2,~ responses. In the second set of 
experiments in which veins for each test group were from 
the same patient, a paired t test was used to compare the 
single KC1 and PGF2~ responses to control responses. 
Effective concentrations for half-maximal responses 
(ECso) were calculated by performing a curve fit on each 
individual vascular ring's dose response. The equation 
chosen for curve fitting was based on receptor theory and 
is detailed elsewhere. 4 Log-normal distribution is ex- 
pected for equieffective doses; therefore, mean logs were 
used in comparing ECso values as previously described. 5 
The ECso values were compared by an unpaired t test in 
Table I and an analysis of variance with Scheffe's test in 
Table II. All data are presented as means plus or minus 
standard error of the mean and only those differences with 
a p value of less than 0.05 were considered statistically 
significant. 
Results 
Veins marked with MB during the operation. A 
total of 12 of  72 unmarked (from 8 men and 4 
women) and 5 of 24 MB-marked (from 3 men and 2 
women) saphenous vein preparations were evalu- 
ated for vascular reactivity. Compared with un- 
marked vessels, those marked with MB showed a 
significant impairment in their ability to contract o 
all vasoconstrictor agents used (Figs. 1 and 2). 
Vasoconstriction to KC1 (Fig. 1, A)  and PGF2~ (Fig. 
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Fig. 3. Vasodilator dose response curves for sodium nitroprusside (A), acetylcholine (B), isoproterenol 
(C), and verapamil (D) obtained from saphenous vein ring preparations that were unmarked (open circles, 
no MB, n = 12/18) ormarked (black circles, MB, n = 5/6) with MB during operations for use in coronary 
artery bypass. Responses are expressed as a percentage ofpreconstriction obtained with PGF2~ 3/xmol/L. 
Symbols on the X-axis depict ECso values for the respective curve. *p < 0.05. 
Table I. ECso values for saphenous veins marked with methylene blue during surgery compared with veins not 
marked 
Drug ECso MB free (n = 5) ECso MB marked (n = 12) 
Phenylephrine 
Serotonin 
Angiotensin II
BHT-933 
Sodium nitroprusside 
Acetylcholine 
Isoproterenol 
Verapamil 
(9.6 _+ 5.2) x 10 -7 mol/L 
(8.2 _+ 4.5) × 10 -s mol/L 
(5.1 _+ 9.1) × 10 9 mol/L 
(1.4 _+ 1.7) × 10 6 mol/L 
(1.8 _+ 0.7) × 10 -7 mol/L 
(4.7 _+ 2.3) × 10 -8 mol/L 
(3.1 _+ 1.9) × 10 -8 mol/L 
(8.4 + 5.3) N 10 -7 mol/L 
(7.1 + 1.8) × 10 -7 mol/L 
(1.6 -+ 0.9) × 10 -7 mol/L 
(9.9 + 10.3) × 10 -9 mol/L 
(8.7 + 3.5) × 10 -7 mol/L 
(1.7 -+ 0.9) × 10 -6 mol/L* 
(4.5 + 4.7) × 10 -7 mol/L* 
(2.0 -+ 0.9) × 10 -7 mol/L* 
(1.3 - 0.7) x 10 -6 mol/L 
*p < 0.05 compared with unmarked vein. 
1, B) in MB-marked versus unmarked vessels was 
reduced by 30% + 10% and 22% -+ 8%, respec- 
tively. Compared with unmarked vessels, the maxi- 
mal contraction of MB-marked saphenous vein, 
expressed in grams of tension, was reduced by 
73% -+ 8%, 53% + 17%, 58% +_ 13%, and 38% + 
12% for phenylephrine (Fig. 2, A), serotonin (Fig. 2, 
B), angiotensin II (Fig. 2, C), and BHT (Fig. 2, D), 
respectively. The same data, expressed as a percentage 
of maximal response to KC1, showed a reduction of 
51% _+ 21%, 45% _+ 22%, 53% _+ 14%, and 36% _+ 
20% for phenylephrine, serotonin, angiotensin II, and 
BHT, respectively. Compared with unmarked vessels, 
those marked with MB showed a significant impair- 
ment in their ability to relax to all vasodilator agents 
used (Fig. 3). MB-marked veins demonstrated a sig- 
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Fig. 4. Maximal vasoconstrictor responses measured ingrams of tension in saphenous veins comparing the 
effect on an experimentally exposed veinto 0.1% MB for 45 minutes abluminally only (black column, 
external; n = 6/12), abluminally a d intraluminally (stippled column, external nd internal; n = 6/12), or not 
exposed to MB (open column, control, n = 6/12). A, the constriction elicited by membrane depolarization 
induced by KC1, 100 mmol/L. B, Constriction elicited by exposure to PGF2~, 3/zmol/L. *p < 0.05 compared 
with control. 
Table II. ECso values for saphenous veins experimentally exposed t  MB (0.1% for 45 minutes) as described 
in methods 
Drug ECso MB free ECso EXT MB ECso INT/EXT MB 
Phenylephrine (1.6 _+ 0.9) × 10 -6 mol/L (5.0 _+ 3.3) × 10 -7 mol/L (9.4 _+ 3.2) × 10 -7 mol/L 
Serotonin (1.6 --+ 0.8) )< 10 -7 molfl_, (1.8 ± 0.8) X 10 -7 mol/g (1.3 --+ 1.0) )< 10 -7 mol/L 
Sodium nitroprusside (3.3 _+ 1.07) × 10 -7 mol/L (6.4 _+ 3.8) × 10 -7 mol/L (1.5 +_ 1.5) >( 10 -6 mol/L* 
Acetylcholine (3.7 +_ 1.6) × 10 -8 mol/L (2.3 _+ 2.3) x 10 .8 mol/L (3.7 +_ 4.5) × 10 .8 mol/L 
All data are from a single saphenous vein divided into three groups from a total of six separate patients. EXT, Vein exposed to MB externally only; INT/EXT, 
vein exposed to MB internally and externally. 
*p < 0.05 compared with MB free vein. 
nificant rightward shift in ECso values for sodium 
nitroprusside and isoproterenol (see Table I). Evalua- 
tion of the nadir of the dilatory dose response curves 
demonstrated that relaxation was reduced by 54% +_ 
17%, 46% + 17%, 53% _+ 14%, and 78% _+ 18% for 
sodium nitroprusside (Fig. 3, A), acetylcholine (Fig. 3, 
B), isoproterenol (Fig. 3, C), and verapamil (Fig. 3, D), 
respectively, when data re expressed as a percentage 
of PGF2~, preconstriction. The same data expressed as 
grams of relaxation showed a similar reduction in the 
MB-marked vessels of 68% _+ 12%, 68% +_ 10%, 
60% _+ 7%, and 82% _+ 6% at the same point of 
sodium nitroprusside, acetylcholine, isoproterenol, 
and verapamil, respectively. 
Veins experimentally exposed to MB. A total of 6 
of 36 unmarked (from 3 men and 3 women) saphe- 
nous vein preparations were evaluated for vascular 
reactivity after experimental exposure to MB. Fig. 4 
demonstrates MB-attenuated vasoconstrictor re- 
sponses to both PGF2~ and KC1 with the greatest 
impairment seen in the external/internal exposure 
group. Compared with control vessels, vessels in the 
external MB group showed a 36% _+ 16% (Fig. 4,A) 
impairment of KC1 constriction and a 33% _+ 19% 
(Fig. 4, B) impairment of PGF2~ constriction. Ves- 
sels in the internal/external MB group showed an 
even greater impairment of both KC1 (40% _+ 16%, 
Fig. 4,A) and PGF2~ constriction (59% + 17%, Fig. 
4, B). Phenylephrine and serotonin dose response 
curves comparing the three experimental groups 
indicate that internal/external MB exposure signifi- 
cantly attenuates the vasoconstrictor ability of sa- 
phenous veins (Fig. 5). Phenylephrine vasoconstric- 
tion in the external MB group was not significantly 
lower than in the control group. However, a trend 
toward a blunted response is evident (Fig. 5, A). For 
serotonin constriction, the external MB group was 
significantly impaired at 10 -7 mol/L (Fig. 5, B). 
Compared with the control group, the maximal 
response of the external MB group to phenylephrine 
and serotonin was reduced by 28% + 19% and 
48% _+ 13%, respectively. For the internal/external 
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Fig. 5. Vasoconstrictor dose response curves for phe- 
nylephrine (A) and serotonin (B) obtained from saphe- 
nous vein ring preparations that were experimentally 
exposed to 0.1% MB for 45 minutes abluminally only 
(black triangles, external, n = 6/12), abluminally and 
intraluminally (black circles, external and internal, n = 
6/12), or not exposed to MB (open circles, control; n = 
6/12). Symbols on the X-axis depict ECso values for the 
respective curve. *p < 0.05 compared with control. 
MB group, the maximal response to phenylephrine 
and serotonin was reduced by 70% -+ 6% and 
58% _+ 16%, respectively. 
Experimental exposure to MB also reduced the 
vasodilatory function of saphenous veins (Fig. 6). 
When the data are expressed as a percentage of 
PGF2~ preconstriction, MB did not significantly 
change acetylcholine relaxation although a clear 
trend is evident (Fig. 6, C). Expressed as a percent- 
age of PGF2~ preconstriction, the internal/external 
MB group demonstrated significant attenuation of 
sodium nitroprusside relaxation by 18% _ 11% 
(Fig. 6, A) at the nadir of the dilator response 
curves. The ECs0 value was also significantly shifted 
rightward, which indicates a decreased sensitivity of 
the internal/external veins to sodium nitroprusside 
(see Table II). When the data are expressed in 
grams of relaxation, both the internal/external and 
external MB groups are significantly inhibited from 
relaxing to sodium nitroprusside by 75% _+ 6% and 
45% _+ 12%, respectively (Fig. 6, B). Significant 
impairment (67% _+ 16%) of acetylcholine vasore- 
laxation in the internal/external group was also 
evident when the data were expressed in grams of 
tension (Fig. 6, D). 
Discussion 
The present study demonstrates that the use of 
MB as an extravascular surgical marker has the 
potential to impair vascular function, particularly 
when MB has access to both the adventitia nd the 
endothelium. In practice, MB can access the endo- 
thelium when the isolated MB-marked vein is briefly 
placed in a storage solution until the time of trans- 
plantation. Leaching of MB on the adventitia into 
the storage solution allows for free diffusion of MB 
into the vessel umen and hence the endothelium. 
The concentration of MB leached into the storage 
solution is not insignificant because the conven- 
tional 1% stock solution of MB is in excess of 500 
times the dose required to irreversibly inhibit endo- 
thelium-derived relaxing factor. 6 Further, results 
from this study indicate that in addition to the well 
documented inhibition of vasodilators, 7 MB also 
diminishes the effects of other vasodilators and 
vasoconstrictors i respective of the route of applica- 
tion. The current study was designed to evaluate 
numerous possible MB pathways through the use of 
a variety of vasoactive agents, but because MB 
caused an impairment of all agents tested, isolation 
of specific mechanisms i  difficult. From a practical 
aspect, the mechanism of MB impairment of vascu- 
lar function is perhaps less important than the clear 
documentation of an effect of MB at clinically 
relevant doses and exposure times. 
The pharmacologic actions of MB have been 
extensively studied but remain poorly understood. 
MB is best known as a direct inhibitor of soluble 
guanylate cyclase, presumably via MB oxidation of 
the guanylate cyclase heme moiety, s The ability of 
MB to inhibit those vasodilators that are thought o 
act by activation of guanylate cyclase is indirect 
evidence of inhibition of the enzyme by MB. 7 This 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 1 
Barber et aL 27 
-20 - 
E 
8 
-40 - 
EL. -60 - 
-80 
.~_ 
-lOO 
r~ 
-120 
~0__0 Control ~ ~ 
External ± ~ T ' ~  
H External& Internal J_ 
t i l © 'V l~ i j 
lO-a 10 ~ 10" 7 10" ~ 10"5 104 
Na ÷ Nitroprusside (log M) 
o C 
-10 
-20 
-3o 
-4O 
10-a 10" a 10-7 10 ~ 10" ~ 104 
Acetylcholine (log M) 
10. g 10 "8 10 .7 10" ~ 10 "s 10" 
Na* Nitroprusside (log M) 
0.00 
-0.15 
-0.60 
-0,75 t i ~ I i I I 
10 .9 10 ~ 10" 7 10 "B 10" 5 10" 
Acetylcholine (log M) 
~-0.30 
o 
× 
--~ -0.45 
Fig. 6. Vasodilator dose response curves for sodium nitroprusside (A and B) and acetylcholine (C and D) 
obtained from saphenous vein ring preparations that were experimentally exposed to 0.1% MB for 45 
minutes abluminally only (black triangles, external, n = 6/12), abluminally and intraluminally (black circles, 
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affected preconstriction, the data are expressed as both a percentage ofPGF2~ preconstriction (A and C) 
and as grams of relaxation (B and D). Symbols on the X-axis depict ECso values for the respective curve. 
*p < 0.05 compared with control. 
includes all endothelium-dependent and-indepen- 
dent vasodilators that elicit vascular smooth muscle 
relaxation by either nitric oxide formation or nitric 
oxide release] Such a mechanism is consistent with 
the change in ECs0 values and inhibition of sodium 
nitroprusside and acetylcholine vasorelaxation ob- 
served in this study. However, an inhibition of 
guanylate cyclase by MB does not explain the im- 
pairment of isoproterenol rverapamil vasodilation. 
Nor does it explain the MB-mediated attenuation of
vasoconstrictor responses een in this study. The 
impairment of vascular reactivity in the current 
study seems to be global rather than specific for a 
given transduction system. MB-mediated reduction 
in the receptor-independent KC1vasoconstriction is 
evidence of the global nature of the impairment of 
vascular eactivity. This is not to say that inhibition 
of guanylate cyclase is an irrelevant mechanism 
contributing to the vascular impairment seen in this 
study. Inhibition of this enzyme is probably occur- 
ring as evidenced by the shift in ECs0 values for 
sodium nitroprusside. However, other MB-medi- 
ated mechanisms of vascular impairment are likely 
dwarfing any guanylate cyclase ffects. 
MB is a more potent inhibitor of endothelium- 
dependent vasodilation mediated by acetylcholine 
than it is of endothelium-independent nitrodila- 
tors.9,10 This suggests that MB acts to inhibit vaso- 
dilation by mechanisms independent of guanylate 
cyclase. A recent study by Marczin, Ryan, and 
Catravas 11 suggests that MB inactivation of guany- 
late cyclase is only a minor pathway for the effects of 
MB. Rather, MB generates superoxide anion, which 
rapidly reacts with and inactivates nitric oxide as a 
vasodilator. 12Marshall, Wei, and Kontos 13 were the 
first to demonstrate hat MB inhibits acetylcholine 
dilation via the production of a reactive oxygen 
species. Subsequently, Wolin and coworkers 14 used 
2 8 Barber et al. 
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the cremaster microcirculation as a model to dem- 
onstrated that suffusion of superoxide dismutase 
readily inhibits the effects of MB on acetylcholine 
and nitric oxide vasodilation. MB is hypothesized to
generate superoxide when the reduced form of MB 
autoxidizes 13 or via an interaction with various 
dehydrogenases. 15 Regardless of the exact mecha- 
nism, MB appears to produce significant amounts of 
superoxide in blood vessels. Moreover, a recent 
study demonstrated that MB generated superoxide 
in a dose- and time-dependent manner in the pres- 
ence, but not absence, of cultured vascular smooth 
muscle cells, m 
The generation of superoxide by MB is a potential 
mechanism of the vascular impairment seen in the 
present study. In vascular tissue, superoxide is con- 
verted to a variety of other potentially harmful 
reactive oxygen species including hydrogen perox- 
ide, hydroxyl ion, and peroxynitrite. 16 Countless 
studies have identified oxygen-derived free radicals 
as mediators of cellular damage, 17' 18 including dam- 
age to vascular tissue. 19 MB-induced oxidative dam- 
age has the potential to affect any number of 
pathways controlling smooth muscle or endothelial 
function 2° and would likely lead to a global impair- 
ment of vascular function as seen in this study. 
Whether this is the mechanism of MB impairment 
remains to be determined. 
MB increases the spontaneous outflow and alters 
the storage of catecholamines from sympathetic 
nerves in vascular tissue. In vitro, MB causes a rise 
in vascular tone that is readily blocked with a-ad- 
renergic agonists. Further, MB inhibits responses to 
both tyramine and electrical stimulation of adrener- 
gic nerves of rabbit perfused ear arteries. 21 Soares- 
Da-Silva and Caramona 22 used canine mesenteric 
arteries to demonstrate that MB releases norepi- 
nephrine and dopamine, decreases accumulation of 
norepinephrine, and inhibits monoamine oxidase 
and catechol-O-methyl transferase. Collectively, 
these studies demonstrate that MB produces a 
prolonged sympathomimetic effect in vascular tis- 
sue. The MB-mediated reduction of adrenergic al, 
a2, and/32 responses in the present study could be 
explained by an adrenergic desensitization resulting 
from the prolonged sympathomimetic effect of MB. 
However, the magnitude of MB impairment was not 
greater in adrenergic than in nonadrenergic re- 
sponses, suggesting other, more global mechanisms. 
Whether the effects of MB on the vascular adrener- 
gic system are clinically relevant when MB is used as 
a marker dye is unknown, but in light of the results 
of the current study, it seems that MB has any 
number of potential mechanisms by which to ad- 
versely affect blood vessels. 
In conclusion, the current study has demonstrated 
that MB applied either luminally or abluminally 
can decrease both the vasoconstrictor and vasodila- 
tory function of human saphenous veins by an 
unknown mechanism. These results, when coupled 
with other studies that have shown that MB pro- 
duces superoxide, inhibits guanylate cyclase, in- 
creases platelet deposition, 23 and elicits a sympatho- 
mimetic response, suggest hat the use of MB as a 
surgical marker is inappropriate until further studies 
can evaluate the potentially detrimental effects of 
MB.  
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